A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Status Active, not recruiting

Clinical Trial Summary

This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE). PXE is a rare disease that is associated with significant risks of visual impairments and comorbidity from peripheral and cardiovascular diseases, and adversely impacts the quality of life in afflicted individuals.

Clinical Trial Description

DS-1211b, a potent small-molecule inhibitor of tissue-nonspecific alkaline phosphatase, is being developed for the treatment ectopic calcification diseases such as PXE. This study will assess DS-1211b (low-, middle-, and high-dose tablets) administered once daily for 12 weeks in individuals with PXE. ;

Study Design

Related Conditions & MeSH terms

Pseudoxanthoma Elasticum

Clinical Trial Details

NCT number	NCT05569252
Study type	Interventional
Source	Daiichi Sankyo, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 20, 2022
Completion date	April 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02537054` - Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)	Phase 2
Recruiting	`NCT05662085` - Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Completed	`NCT03070860` - What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum	N/A
Completed	`NCT01446393` - Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)	N/A
Completed	`NCT00470977` - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy	Phase 1/Phase 2
Recruiting	`NCT03758534` - Natural History of GACI With or Without ARHR2 or PXE
Recruiting	`NCT01446380` - Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort	N/A
Recruiting	`NCT03813550` - Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)	N/A
Not yet recruiting	`NCT03364504` - Biological Collection of Kidney Cells	N/A
Active, not recruiting	`NCT02108392` - Characterization of Pseudoxanthoma Elasticum
Recruiting	`NCT01731080` - Arterial Wall Calcium Load in Pseudoxanthoma Elasticum	N/A
Completed	`NCT00555113` - Evolution of Visual Impairment During Pseudoxanthoma Elasticum	N/A
Completed	`NCT00341419` - Genetic Analysis of Patients With Pseudoxanthoma Elasticum
Withdrawn	`NCT04441671` - Oral Pyrophosphate Absorption in PXE Disease	Phase 2
Recruiting	`NCT04868578` - PPI Supplementation to Fight ECtopIc Calcification in PXE	N/A
Completed	`NCT05025722` - Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
Completed	`NCT01525875` - Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)	Phase 2
Completed	`NCT05246189` - Employment of Patients With Pseudoxanthoma Elasticum
Recruiting	`NCT05832580` - The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum	Phase 3
Active, not recruiting	`NCT05030831` - Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE	Phase 1/Phase 2